A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX) - TrilynX

Merck Healthcare KGaA, an affiliate of Merck KGaA, Darmstadt, Germany0 个研究点目标入组 700 人开始时间: 2020年7月28日最近更新: 2024年9月2日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 700

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Willing and able to sign written informed consent prior to study screening.
•2. Male or female = 18 years of age (or based on the country legal age limit for adults) on day of signing the ICF.
•3. Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
•4. Histologically confirmed diagnosis in previously untreated LA-SCCHN patient (stage III, IVA or IVB according to the American Joint Committee on Cancer [AJCC]/TNM Staging System, 8th Ed.) suitable for definitive CRT as defined in the protocol.
•5. Evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by computed tomography scan (CT-scan) or magnetic resonance imaging (MRI), based on RECIST v 1.1.
•6. For OPC patients, primary tumors must be HPV-negative as determined by p16 expression using immunohistochemistry (IHC). For OPC participants, p16 cutoff for determination of HPV status is defined in the protocol.
•7. Able to swallow liquids or has an adequately functioning feeding tube, gastrostomy or jejunostomy in place.
•8. No hearing loss by clinical assessment or =Grade 2 hearing
•impairment (according to NCI- CTCAE v.5).
•9. Peripheral neuropathy < grade 2
•10. Adequate hematologic, renal and hepatic function as defined in the protocol.
•11. Women of childbearing potential (according to recommendations of the Clinical Trial Facilitation Group) must have a negative serum pregnancy test at screening and must not be breastfeeding. Non-sterilized males who are sexually active with a female partner of childbearing potential must agree to use adequate birth control as defined in the protocol from ICF signature to 6 months after the last administration of chemotherapy or 3 months after the last dose of Xevinapant / matched placebo, whichever is the latest.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 600
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 100

排除标准

•1. Primary tumor of nasopharyngeal, paranasal sinuses, nasal or oral cavity, salivary, thyroid or parathyroid gland pathologies, skin or unknown primary site.
•2. Metastatic disease (stage IVC as per AJCC/TNM, 8th Ed.).
•3. Prior definitive or adjuvant RT and/or radical surgery to the head and neck region which may jeopardize the primary tumor irradiation plan, or any other prior SCCHN systemic treatment, including investigational agents.
•4. Use within 14 days prior to randomization or requirement for ongoing treatment with any drug(s) on the prohibited medication list.
•5. Treatment with an investigational agent or use of an investigational device within 4 weeks of the first dose of study treatment.
•6. Known history of infection with HIV. If unknown history of HIV, an HIV screening test is to be performed and participants with positive serology for HIV-1/2 must be excluded.
•7. Known chronically active HBV or HCV infection. If unknown status, see further details in the protocol.
•8. Other infections (viral and/or bacterial and/or mycotic) requiring systemic treatment.
•9. Live-attenuated vaccinations within 30 days prior to first investigational treatment administration.
•10. Ongoing uncontrolled infection requiring intravenous antibiotic therapy within 1 week prior to randomization.
•11. Known gastrointestinal disorder with clinically established malabsorption syndrome and major gastrointestinal surgery that may limit oral absorption.
•12. Documented weight loss of >10% during the last 4 weeks prior to randomization (unless adequate measures are undertaken for nutritional support), OR plasmatic albumin <3.0 g/dL.No albumin transfusions are
•allowed within 2 weeks before randomization.
•13. Active gastrointestinal bleeding, or any other uncontrolled bleeding requiring more than 2 red blood cell transfusions or 4 units of packed red blood cells within 4 weeks prior to randomization.
•14. Active uncontrolled inflammatory disease (including rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, severe extensive psoriasisand other autoimmune diseases) requiring ongoing treatment with anti-TNF medication.
•15. Any concomitant medication known to prolong the QT interval that cannot be discontinued or replaced by safe alternative medication within 7 days prior to start of treatment.
•16. Impaired cardiovascular function or clinically significant cardiovascular diseases, see further details in the protocol.
•17. Symptomatic pulmonary disease requiring continuous or intermittent oxygen supply.
•18. History of another malignancy within the last 3 years prior to randomization, with the exception of completely resected non-melanoma cell skin cancer outside the head and neck area or completely resected stage I breast cancer, or completely resected in-situ non-muscular invasive bladder, cervix and/or uterine carcinomas, or T1a squamous cell carcinoma of the esophagus.
•19. Known contraindication to undergoing positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (18F-FDG-PET) scans, and/ or both contrast-enhanced MRI and contrast-enhanced CT scans.
•20. Known allergy to Xevinapant, cisplatin, carboplatin, other platinum-based agent or any excipient known to be present in any of these products or in the placebo formulation.
•21. Non-compensated or symptomatic liver cirrhosis (Child-Pugh score: B or C).
•22. Any ongoing condition or disorder, before randomization, including drug(s) or alcohol abuse, which in th

研究者

发起方

Merck Healthcare KGaA, an affiliate of Merck KGaA, Darmstadt, Germany

相似试验

进行中（未招募）

1 期

A clinical trial in patients with head and neck cancer of Debio 1143 in combination with platinum-based chemotherapy and radiotherapyocally advanced squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 21.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-000377-25-CZDebiopharm International S.A.700

进行中（未招募）

1 期

A clinical trial in patients with head and neck cancer of Debio 1143 in combination with platinum-based chemotherapy and radiotherapyocally advanced squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 26.1Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-000377-25-PTMerck Healthcare KGaA, an affiliate of Merck KGaA, Darmstadt, Germany700

进行中（未招募）

1 期

EUCTR2020-000377-25-GRMerck Healthcare KGaA, an affiliate of Merck KGaA, Darmstadt, Germany705

进行中（未招募）

1 期

A clinical trial in patients with head and neck cancer of Debio 1143 in combination with platinum-based chemotherapy and radiotherapyocally advanced squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 26.1Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-000377-25-ATMerck Healthcare KGaA, an affiliate of Merck KGaA, Darmstadt, Germany700

进行中（未招募）

1 期

A clinical trial in patients with head and neck cancer of Debio 1143 in combination with platinum-based chemotherapy and radiotherapy

EUCTR2020-000377-25-FRDebiopharm International S.A.700